Tetagam P pre-filled syringes

Marketed by Dexa Medica

Ingredients in every ml

Tetanus Immunoglobulin 250 IU

Each package contains

1 syringe of 1 ml

Other details

Dosage form:Syringe; pre-filled
Flavour: None

W.H.O. classification

ATC Level 1: J - Antiinfectives for systemic use
ATC Level 2: J06 - Immune Sera and Immunoglobulins
ATC Level 3: J06B - Immunoglobulins

Warnings

Pregnancy

SAFE IF PRESCRIBEDThis item is safe for use during pregnancy.

Lactation

SAFE IF PRESCRIBEDThis item is safe for use during lactation.

Alcohol

CONSULT YOUR DOCTORSafety of this item for use with alcohol has not been established. Please consult your doctor.

Machinery

SAFE IF PRESCRIBEDThis item is safe for use while operating heavy machinery.

Available in

Indonesia

Dosage information

FOR ALL AGES
Prophylaxis of tetanus prone wounds:
250 IU combinations with 0.5 ml of absorbed tetanus vaccine at contralateral sites of the body unless the risk is through to be extremely high. The dose may be increased to 500 IU in case of:
– Infected wounds where surgically appropriate treatment cannot be achieved within 24 hours
– Deep or contaminated wounds with tissue damage and reduced oxygen supply; as well as foreign-body injury (e.g., bites, stings or shots)
– Extensive burns, congelations
– Tissue necrosis
– Septicaemic abortion
In case of extensive burns it is advisable to administer a second injection of 250 IU Tetagam at 3-4 weeks interval if the patient is immunosuppressed or if active immunization with tetanus vaccine is contraindicated.
Children and Adults are to receive the same dose

Therapy of clinically manifest tetanus:
Single doses of 3000 to 6000 IU (in combination with other appropriate clinical procedures). Regarding frequency, interval of injection and duration of therapy repeated doses depend on the clinical picture.

Indication

Postexposure prophylaxis
immediate prophylaxis after tetanus prone injuries in patients
– Not adequately vaccinated
– Whose immunisation status is not known with certainty
– With severe deficiency in antibody production.

Therapy of clinically manifest tetanus
Tetanus immunoglobulin should always be administered in conjunction with an active tetanus vaccination unless there are contraindications or confirmation of adequate vaccination.

Disclaimer

The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for informational purposes only. This tool may not cover all possible drug interactions or all warnings or alerts. Please check with a physician if you have health questions or concerns about interactions or go to the appropriate government authority for a comprehensive list of medical warnings. Although we attempt to provide accurate and up-to-date information, no guarantee is made to that effect.

All of the content present on this website, including written text, photographs, videos, graphics, and other resources we might include (these will fall under the collective term of “website”), is meant to educate and should not be perceived as a substitution for professional medical advice, diagnosis or treatment. You should not resort to the website information to arrive at a diagnosis or treatment solution for your health problems or various medical conditions. It does not replace medical care, provided by a medical specialist. In the situation, you have specific symptoms and you might suspect that you are suffering from a medical problem, it is for the best to consult your physician.